Clinical results of HDR brachytherapy

The reported outcomes of combination of HDR brachytherapy and EBRT are favorable (Table 3). Multiple reports of low- and intermediate-risk patients treated with combination of HDR brachytherapy and EBRT have demonstrated excellent long-term biochemical control rates of 90-100% and 87-98%, respectively (Table 3). Long-term biochemical control rate for high-risk patients treated with combination of HDR brachytherapy and EBRT is also favorable.

Yoshioka et al. [99] have performed HDR brachytherapy as monotherapy for localized prostate cancer since 1996. The 5-year bRFS rate for low-, intermediate-, and high-risk patients was 85%, 93%, and 79%, respectively.

Authors

N

Mean/Median

bRFS rate

Follow-up

Low-risk

Intermediate-risk

High-risk

Boost

Astrom et al.

214

4 years

5-year

[100]

92%

88%

61%

Bachand et al.

153

44 months

9 Gy x 2/ 10 Gy x

5-year

[101]

2

95.9%

95.5%

Chen et al. [84]

85

40 months

4-year

5.5 Gy x 3

100%

91%

81%

Demanes et al.

209

6.4 years

5.5 Gy x 4/ 6.0

10-year

[85]

Gy x 4

92%

87%

63%

Yamada et a.l

105

44 months

5.5 Gy x 3/ 7.0

5-year

[86]

Gy x 3

100%

98%

92%

Phan et al. [89]

309

59 months

5-year

6 Gy x 4

98%

90%

78%

Prada et al.

313

71 months

10-year

[102]

11.5 Gy x 2

100%

91%/88%

79%

Monotherapy

Yoshioka et al.

112

5.4 years

5-year

[99]

85%

93%

79%

Rogers CL et al.

284

35.1 months

5-year

[103]

94.40%

Table 3. HDR brachytherapy

Table 3. HDR brachytherapy

0 0

Post a comment